# Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma

> **NCT00193973** · PHASE2 · COMPLETED · sponsor: **Trans Tasman Radiation Oncology Group** · enrollment: 20 (actual)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT00193973
- **Lead sponsor:** Trans Tasman Radiation Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2008-07
- **Final completion:** 2013-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193973, "Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00193973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*